Back

Post-prandial acyl ghrelin infusion in heart failure patients increases gastric emptying rate

2 September 2024 (10:00 - 10:30)
Organised by: Logo
Congress Presentation Part of: Comorbidities in heart failure: new insights Comorbidities ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Associate Professor Camilla Hage

Karolinska University Hospital, Stockholm (Sweden)

5 More presentations in this session

Presentation thumbnail
Obesity and renal impairment in patients with heart failure and reduced ejection fraction: another obesity paradox?
Doctor S. Matsumoto (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
A graded association between mobility limitation and prognosis in patients with heart failure
Doctor K. Iwatsu (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
Prognostic value of sarcopenia defined by the Sarcopenia Definitions and Outcomes Consortium criteria in patients with heart failure
Doctor T. Nakade (Tokyo, JP)
Abstract Slides Video
Presentation thumbnail
The impact of exogenous ketone body suppletion on energy and pH balance in skeletal muscle during exercise in chronic heart failure patients: a prospective randomized double-blind cross-over study
Ms S. Voorrips (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Accelerometer-measured physical activity pattern in older patients with frailty and heart failure
Doctor S. Sze (Leicester, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Comorbidities in heart failure: new insights

The Event

Event poster

ESC Congress 2024

2 September 2024 10:00 CET
You may be interested in
thumbnail
Congress Presentation
Acyl ghrelin increases cardiac output and preserves right ventricular-pulmonary arterial coupling in patients with heart failure
thumbnail
Congress Presentation
MetAnEnd-HF - Translational and clinical aspects of metabolic, anabolic and endothelial dysfunction in heart failure
thumbnail
Congress Presentation
Randomized, double-blind, placebo-controlled, safety, tolerability, PK, PD and exploratory efficacy phase 1b/2a trial with AC01 in patients with HFrEF

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources